Tuesday 20 February 2018
Contact US    |    Archive
PR
5 months ago

U.S. FDA Accepts for Review Astellas Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

TOKYO, Sept. 12, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

FDA

 | 

Accepts

 | 

for

 | 

Review

 | 

Astellas

 | 

Supplemental

 | 

New

 | 

Drug

 | 

Application

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries